Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from SymBio Pharmaceuticals Limited was processed by Pulse News Wire on April 17, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
TOKYO, Apr 17 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582) announced a third-party allotment of stock options. KEY TERMS: - Warrants to be issued: 30,827 - Shares per warrant: 100 - Maxi
View all SymBio Pharmaceuticals Limited disclosures →
SymBio Pharmaceuticals Limited [4582.T]
TOKYO, Apr 17 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582) announced a third-party allotment of stock options.
KEY TERMS: - Warrants to be issued: 30,827 - Shares per warrant: 100 - Maximum dilution: 3,082,700 shares
🟢 Confidence: High AI-translated content.